Product
Navepegritide
1 clinical trial
1 indication
Indication
AchondroplasiaClinical trial
A Phase 2, Multicenter, Double-Blind, Randomized, Placebo-controlled Trial, Evaluating Safety, Tolerability, and Efficacy of Subcutaneous Doses of TransCon CNP Administered Once Weekly for 52 Weeks in Infants (0 to <2 Years of Age) With Achondroplasia Followed by an Open Label Extension (OLE) PeriodStatus: Recruiting, Estimated PCD: 2026-03-01